GoKawiilSign up to see the future, today Can’t-miss innovations from the bleeding edge of science and tech Email address Sign Up Thank you!
These days, large language models are pushing the line between schizophrenic break and reality closer than ever before.
In a wild new post that’s going viral on X-formerly-Twitter, an enterprising young biochemist named Douglas Yao showcased a new drug he’s been developing with the aid of ChatGPT. He’s not employed by any pharma company, and his drug lab is setup on a couple folding tables in his garage.
Specifically, Yao enthuses about a new drug he calls “PAC-3310,” which he says is meant to treat schizophrenia. “It was designed by ChatGPT,” Yao explains, “and I synthesized it in a chemistry lab I built in my garage.”
The result is a small vial of yellow powder — the first sample of 3310, apparently — which Yao says is modeled after the recently-authorized antipsychotic Cobenfy, “but improved.”
This vial contains a new drug called PAC-3310. It was designed by ChatGPT, and I synthesized it in a chemistry lab I built in my garage.
PAC-3310 is a new selective M4 muscarinic receptor agonist for treating schizophrenia – similar to the recent breakthrough drug Cobenfry, but… pic.twitter.com/o7z6iLR50T — Douglas Yao (@DouglasYaoDY) September 8, 2026
On his GitHub page, Yao boasts that he’s used AI to “design several thousand new small molecule drugs” over the past year, including a “new Alzheimer’s drug,” which he’s developing in addition to the schizophrenia treatment.
“I then taught myself synthetic chemistry, built a chem lab in my garage, and synthesized a hundred of them,” he continued. “I’m now testing these compounds in cell lines and mice.”
... continue reading